Cornerstone rises on FDA acceptance of hyponatremia drug NDA
This article was originally published in Scrip
Executive Summary
Shares of Cornerstone Therapeutics climbed as high as 9.2% in morning trading on 13 March after it revealed that the US FDA had accepted the new drug application (NDA) for the company's investigational hyponatremia treatment CRTX 080, a highly potent oral non-peptide, which acts on the vasopressin-2 receptor in the kidneys, causing water to be excreted while sparing sodium without affecting other electrolytes.